Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Canopy Growth vs. Scotts Miracle-Gro

By Keith Speights - Mar 8, 2020 at 9:35AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A pure-play pot stock and a top supplier to the cannabis industry. Which is the better choice for long-term investors?

I watched a few minutes of Nik Wallenda walking a high-wire across an active volcano last week. There were a few dicey spots where the wind kicked up, but I really was never in doubt that he would make it all the way. And he did.

That's kind of the way I see the global cannabis industry. There have been some stiff headwinds. There have been some dicey spots. But I still think the cannabis market will grow to be much larger than it is right now.

Two of the top players in the cannabis market are Canopy Growth (CGC -3.05%) and Scotts Miracle-Gro (SMG -1.35%). Although their business models are quite different, both companies seem to have what it takes to go the distance. But which stock is the better pick for long-term investors? 

Cannabis leaves on top of $100 bills

Image source: Getty Images.

The case for Canopy Growth

Canada boasts the largest market in the world where cannabis is legal nationwide. And Canopy Growth claims the biggest market share in that market.

Look for the Canadian market to grow significantly over the next few years. The Cannabis 2.0 market for cannabis derivatives products is just getting started. Ontario, Canada's most heavily populated province, is finally starting to issue more much-needed retail cannabis licenses. Canopy Growth should be among the biggest winners -- and probably the biggest winner -- from these developments.

But there's an even larger opportunity in international cannabis markets. Canopy Growth is already one of the leading suppliers of medical cannabis in Germany. It also has operations in other European nations, including Denmark and the United Kingdom, in Latin America, in southern Africa, and in Australia. 

The most important cannabis opportunity of all, though, is in the U.S. Canopy Growth can't enter the U.S. marijuana market and keep its shares listed on major stock exchanges. However, the company is poised to immediately jump into the U.S. should federal marijuana laws change thanks to its option to acquire U.S.-based Acreage Holdings. It's also already marketing hemp-based CBD products in the U.S., which isn't a problem since hemp is legal at the federal level.

Canopy Growth's greatest competitive advantage is its relationship with Constellation Brands. The U.S. alcoholic beverage maker owns 37% of Canopy. The $4 billion-plus that Canopy received from Constellation puts the company in an enviable position in the cannabis industry. 

What's the biggest knock against Canopy Growth? Its lack of profitability. However, the company is taking steps to curtail spending, including shutting down two greenhouses in British Columbia. With increased fiscal discipline and growing revenue, Canopy now appears to be on a path to profitability. 

The case for Scotts Miracle-Gro

Scotts Miracle-Gro is best known for its consumer lawn and garden products. The company made roughly 45% of its total revenue from this business in its fiscal 2020 first quarter. 

And Scotts' consumer lawn and garden products continue to deliver solid growth. The company's launches of new organic products have been very successful. Longer spring and summer seasons could boost sales even more in the future.

The real growth story for Scotts Miracle-Gro, though, is with its Hawthorne segment, which focuses on supplying gardening products to the cannabis industry. The segment's revenue jumped 41% year over year in Q1 to $198.8 million.

A significant portion of Hawthorne's growth has come as a result of acquisitions. However, the business has also benefited from a rebound in California's cannabis market as well as other expanding cannabis markets in Colorado, Michigan, Illinois, and Florida.

Scotts is poised to experience even more growth as more states legalize either medical or recreational marijuana and as existing cannabis markets mature. The company would also be a big winner if the U.S. legalizes marijuana at the federal level.

Unlike Canopy Growth, Scotts Miracle-Gro is already consistently profitable and has been for a long time. The company even pays a dividend with a yield of nearly 2%. 

Better buy

Canopy Growth could deliver the biggest gains over the long run. But I think that Scotts Miracle-Gro is the safer pick.

Marijuana stocks can be extremely volatile. Scotts' solid financial position and cushion from its consumer lawn and garden business make it less risky than most stocks with cannabis connections, in my view. Like Nik Wallenda in his tight-wire walk across a volcano, Scotts Miracle-Gro has a safety net.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Scotts Miracle-Gro Company Stock Quote
The Scotts Miracle-Gro Company
$80.31 (-1.35%) $-1.10
Canopy Growth Stock Quote
Canopy Growth
$3.50 (-3.05%) $0.11
Constellation Brands, Inc. Stock Quote
Constellation Brands, Inc.
$243.63 (-0.77%) $-1.89
Acreage Holdings, Inc. Stock Quote
Acreage Holdings, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.